Long-term efficacy and safety of ruxolitinib versus best available therapy in polycythaemia vera (RESPONSE): 5-year follow up of a phase 3 study - Concepedia

Concepedia

Publication | Open Access

Long-term efficacy and safety of ruxolitinib versus best available therapy in polycythaemia vera (RESPONSE): 5-year follow up of a phase 3 study

DOI Full Paper Access

138

Citations

16

References

2020

Year

Jean‐Jacques Kiladjian, Pierre Zachée, Masayuki Hino, Fabrizio Pane, Tamás Masszi, Claire Harrison, Ruben A. Mesa, Carole B. Miller, Francesco Passamonti, Simon Durrant,

The Lancet Haematology

Polycythaemia VeraMedicineHematologyPharmacologyPharmacotherapyRuxolitinib VersusOncologyAvailable Therapy

References

	Year	Citations

Page 1

Page 1